Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0851184 (thinning)
 11,252 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The response of mouse ear epidermal transglutaminase to single applications of anthralin, retinoic acid (both 59 micrograms/ear) or fluocinolone acetonide (2 micrograms/ear) was determined. Anthralin and retinoic acid caused inflammation and accumulation of epidermal protein and DNA, whereas fluocinolone acetonide resulted in ear thinning and decreased epidermal protein and DNA. Treatment with either anthralin or retinoic acid caused increases in absolute amounts of epidermal transglutaminase activity/ear. Anthralin increased this parameter 70-100% above acetone-treated controls from 48 hr through 7 days. Retinoic acid-treated ears showed a slower initial increase but peaked at 4 times control level by 96 hr before returning to normal at 7 days. Fluocinolone acetonide treatment had no effect on this parameter. The specific activity of epidermal transglutaminase (total epidermal transglutaminase/total soluble epidermal protein) was decreased by retinoic acid treatment; was maintained at normal levels by anthralin (except for the 7-day point where it decreased 50%); and was dramatically stimulated by fluocinolone acetonide. In the latter case, specific activity was more than 5 x control by 96 hr and still near this level at 7 days. Epidermal transglutaminase activity is a marker of differentiation, and protein and DNA accumulation an indication of growth. Thus, at the doses studied, retinoic acid favors growth over differentiation, anthralin maintains a normal to near normal ratio of growth to differentiation, and fluocinolone acetonide strongly favors differentiation over growth.
 ...
PMID:The effect of topical drugs on mouse ear epidermal transglutaminase activity. 612 46

Dithranol, 10-propionyl dithranol and 10-butyryl dithranol were compared as regards their antipsoriatic, staining and irritative properties. They were applied under 12-mm Finnchambers on the lesional skin of 17 psoriasis patients every second day for 20 days. In 9 patients their concentration was equimolar (2 mmol/kg of white petrolatum) corresponding to 0.05% dithranol, and in 8 patients the concentrations were 2, 4, and 8 mmol for dithranol, 10-propionyl dithranol and 10-butyryl dithranol, respectively. Without regard to the concentration, they all produced under occlusion almost equal thinning of the lesions, but when a 2 mmol concentration was used, 10-butyryl dithranol (butantrone) showed least staining and irritation on the treated sites.
 ...
PMID:Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone). 620 85